Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Dyne Therapeutics Q2 2024 GAAP EPS $(0.70) Beats $(0.72) Estimate

Author: Benzinga Newsdesk | August 12, 2024 05:19pm
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.72) by 2.78 percent. This is a 35.19 percent increase over losses of $(1.08) per share from the same period last year.

Posted In: DYN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist